脂肪性肝纤维化小鼠模型研究现状

王欣; 胡义扬; 冯琴

doi:10.3969/j.issn.1001-5256.2019.08.049

脂肪性肝纤维化小鼠模型研究现状

DOI: 10.3969/j.issn.1001-5256.2019.08.049

1 上海中医药大学附属曙光医院
2 上海市中医临床重点实验室
3 肝肾疾病病证教育部重点实验室

基金项目:

国家自然基金面上项目(81573668);国家自然基金重点项目(81830119)；国家科技重大专项“重大新药创制”项目(2018ZX09201001-001-002)；上海市科委科技创新行动计划项目(18401933100)；

详细信息

中图分类号: R575;R-332
计量
- 文章访问数: 1123
- HTML全文浏览量: 47
- PDF下载量: 267
- 被引次数: 0
出版历程
- 收稿日期: 2019-05-21
- 出版日期: 2019-08-20

Current status of research on mouse models of nonalcoholic fatty liver fibrosis

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Research funding:

摘要

摘要:
脂肪性肝纤维化是目前非酒精性脂肪性肝病领域研究的重点。研究其发病机制,探索临床治疗药物是该领域亟待解决的问题之一。动物模型是基础研究的重要工具。小鼠模型因其易感性、经济性且基因组与人类高度同源,成为脂肪性肝纤维化应用最广泛的动物模型。综述了目前常用的营养因素诱发、基因敲除或突变以及多因素复合诱导的多种小鼠脂肪性肝纤维化模型的造模方法、模型特点等,旨在为本病基础研究中模型工具的选择提供参考。
- 脂肪性肝纤维化 /
- 模型,动物 /
- 小鼠
Abstract:
At present, nonalcoholic fatty liver fibrosis is one of the highlights of the research on nonalcoholic fatty liver disease (NAFLD) , and there is an urgent need for exploring its pathogenesis and treatment drugs in clinical practice. Animal model is an important tool for basic research, and the mouse model becomes the most widely used animal model of nonalcoholic fatty liver fibrosis because of susceptibility, low costs, and genomes highly homologous to those of the human being. This article reviews the methods for establishing a mouse model of nonalcoholic fatty liver fibrosis, including nutritional factor, gene knockout or mutation, and induction with various factors, as well as the features of these models, in order to provide a reference for the selection of model tools in the basic research on this disease.
- non-alcoholic fatty liver fibrosis /
- animal models /
- mice

HTML全文

参考文献(48)

[1] LI J. Epidemiology characteristics of nonalcoholic fatty liver disease in Asia[J]. J Clin Hepatol, 2018, 34 (12) :2515-2519. (in Chinese) 李婕.亚洲地区非酒精性脂肪性肝病的流行病学特点[J].临床肝胆病杂志, 2018, 34 (12) :2515-2519.

[2] CHOLANKERIL G, PERUMPAIL RB, PHAM EA, et al. Nonalcoholicfatty liver disease:Epidemiology, natural history, and diagnosticchallenges[J]. Hepatology, 2016, 64 (3) :954.

[3] NEGASH AA, GALE M. Hepatitis regulation by the inflammasome signaling pathway[J]. Immunol Rev, 2015, 265 (1) :143-155.

[4] SCHUPPAN D, SURABATTULA R, WANG XY. Determinants of fibrosis progression and regression in NASH[J]. J Hepatol, 2018, 68 (2) :238-250.

[5] European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol, 2016, 64 (6) :1388-1402.

[6] BEDOASSA P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease[J]. Hepatology, 2014, 60 (2) :565-575.

[7] KIRSCH R, CLARKSON V, SHEPHARD EG, et al. Rodent nutritional model of non-alcoholic steatohepatitis:Species, strain and sex difference studies[J]. J Gastroenterol Hepatol, 2003, 18 (11) :1272-1282.

[8] MELLS JE, ANANIA FA. The role of gastrointestinal hormones in hepatic lipid metabolism[J]. Semin Liver Dis, 2013, 33 (4) :343-357.

[9] ITO M, SUZUKI J, TSUJIOKA S, et al. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet[J]. Hepatol Res, 2007, 37 (1) :50-57.

[10] ZHONG L, HUANG L, XUE Q, et al. Cell-specific elevation of Runx2 promotes hepatic infiltration of macrophages by upregulating MCP-1 in high-fat diet-induced mice NAFLD[J]. J Cell Biochem, 2019.[Epub ahead of print]

[11] SAVARD C, TARTAGLIONE EV, KUVER R, et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis[J]. Hepatology, 2013, 57 (1) :81-92.

[12] SPRUSS A, KANURI G, WAGNERBERGER S, et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice[J]. Hepatology, 2009, 50 (4) :1094-1104.

[13] SCHULTZ A, BARBOSA-DA-SILVA S, AGUILA MB, et al.Differences and similarities in hepatic lipogenesis, gluconeogenesis and oxidative imbalance in mice fed diets rich in fructose or sucrose[J]. Food Funct, 2015, 6 (5) :1684-1691.

[14] ASGHARPOUR A, CAZANAVE SC, PACANA T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer[J]. J Hepatol, 2016, 65 (3) :579-588.

[15] KOHLI R, KIRBY M, SOFTIVC S, et al. High-fructose, medium-chain-trans-fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis[J]. Hepatology, 2010, 52 (3) :934-944.

[16] LEE O, BRNCE WR, DONG Q, et al. Fructose and carbonyl metabolites as endogenous toxins[J]. Chem Biol Interact, 2009, 178 (1-3) :332-339.

[17] VOS MB, LAVINRE JE. Dietary fructose in nonalcoholic fatty liver disease[J]. Hepatology, 2013, 57 (6) :2525-2531.

[18] FENG B, YAO PM, LI Y, et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages[J]. Nat Cell Biol, 2003, 5 (9) :781-792.

[19] HUANG HY, XIN YN, JIANG M, et al. Research advances in animal models of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2014, 30 (9) :948-953. (in Chinese) 黄海燕, 辛永宁, 姜曼, 等.非酒精性脂肪性肝病动物实验模型研究进展[J].临床肝胆病杂志, 2014, 30 (9) :948-953.

[20] MATSUZAWA N, TAKAMURA T, KURITA S, et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet[J]. Hepatology, 2007, 46 (5) :1392-1403.

[21] ANSTEE QM, GLODIN RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research[J]. Int J Exp Path, 2006, 87 (1) :1-16.

[22] BAE UJ, PARK EO, PARK J, et al. Gypenoside UL4-rich gynostemma pentaphyllum extract exerts a hepatoprotective effect on diet-induced nonalcoholic fatty liver disease[J].Am J Chin Med, 2018, 46 (6) :1315-1332.

[23] YAMADA T, OBATA A, KASHIWAGI Y, et al. Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice[J]. Magn Reson Imaging, 2016, 34 (6) :724-729.

[24] RINALLA ME, GREEN RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance[J]. J Hepatol, 2004, 40 (1) :47-51.

[25] NAKAE D, MIZUMOTO Y, ANDOH N, et al. Comparative changes in the liver of female fischer-344 rats after short-term feeding of a semipurified or a semisynthetic L-amino acid-defined choline-deficient diet[J]. Toxicol Pathol, 1995, 23 (5) :583-590.

[26] IBRAHIM SH, HIRSOVA P, MALHI H, et al. Animal models of nonalcoholic steatohepatitis:Eat, delete, and inflame[J]. Dig Dis Sci, 2016, 61 (5) :1325-1336.

[27] HEBBARD L, GEORGE J. Animal models of nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2011, 8 (1) :34-44.

[28] SHIMANO R, NISHIMURA K, AKIYAMA H, et al. Interferon-βmediates signaling pathways uniquely regulated in hepatic stellate cells and attenuates the progression of hepatic fibrosis in a dietary mouse model[J]. J Interferon Cytokine Res, 2015, 35 (6) :464-473.

[29] SHIMANO H, AMEMIYA-KUDO M, TAKAHASHI A, et al.Sterol regulatory element-binding protein-1c and pancreaticβ-cell dysfunction[J]. Diabetes Obes Metab, 2007, 9 (Suppl 2) :133-139.

[30] SHIMOMURA I, HAMMER RE, RICHARDSON JA, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue:Model for congenital generalized lipodystrophy[J]. Genes Dev, 1998, 12 (20) :3182-3194.

[31] NAKAYAMA H, OTABE S, UENO T, et al. Transgenic mice expressing nuclear sterol regulatory element-binding protein1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis[J]. Metabolism, 2007, 56 (4) :470-475.

[32] WADA T, MIYASHITA Y, SASAKI M, et al. Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet[J]. Am J Physiol Endocrinol Metab, 2013, 305 (11) :e1415-e1425.

[33] BELL-ANDERSON KS, AOUAD L, WILLIAMS H, et al. Coordinated improvement in glucose tolerance, liver steatosis and obesity associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice[J]. Int J Obes (Lond) , 2011, 35 (12) :1539-1548.

[34] FARRELL GC, MREDHA AR, YEH MM, et al. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype[J]. Liver Int, 2014, 34 (7) :1084-1093.

[35] TRAK-SMAYRA V, PARADIS V, MASSART J, et al. Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet[J]. Int J Exp Pathol, 2011, 92 (6) :413-421.

[36] YOO NY, JEON S, NAM Y, et al. Dietary supplementation of genistein alleviates liver inflammation and fibrosis mediated by a methionine-choline-deficient diet in db/db Mice[J]. J Agric Food Chem, 2015, 63 (17) :4305-4311.

[37] WANG B, CHANDRASEKERA PC, PIPPIN J, et al. Leptinand leptin receptor-deficient rodent models:Relevance for human type 2 diabetes[J]. Curr Diabetes Rev, 2014, 10 (2) :131-145.

[38] CHOI SY, FONG LG, KIRVEN MJ, et al. Use of an anti-low density lipoprotein receptor antibody to quantify the role of the LDL receptor in the removal of chylomicron remnants in the mouse in vivo[J]. J Clin Invest, 1991, 88 (4) :1173-1181.

[39] JACOBS A, WARDA AS, VERBEEK J, et al. An overview of mouse models of nonalcoholic steatohepatitis:From past to present[J]. Curr Protoc Mouse Biol, 2016, 6 (2) :185-200.

[40] LYTLE KA, WONG CP, JUMP DB. Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/-mice[J]. PLo S One, 2017, 12 (4) :e0173376.

[41] FERRE N, MARTINEZ-CLEMENTE M, LOPEZ-PARRA M, et al. Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice:Potential involvement of oxysterols[J]. Am J Physiol Gastrointest Liver Physiol, 2009, 296 (3) :g553-g562.

[42] SCHIERWAGEN R, HITTATIYA K, ZIMMER S, et al. Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis[J]. Sci Rep, 2015, 5:12931.

[43] HONDA T, ISHIGAMI M, LUO F, et al. Branched-chain amino acids alleviate hepatic steatosis and liver injury in cholinedeficient high-fat diet induced NASH mice[J]. Metabolism, 2017, 69:177-187.

[44] IKAWA-YOSHIDA A, MATSUO S, KATO A, et al. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet[J]. Int J Exp Path, 2017, 98 (4) :221-233.

[45] WEBER LW, BOLL M, STAMPFL A. Hepatotoxicity and mechanism of action of haloalkanes:Carbon tetrachloride as a toxicological model[J]. Crit Rev Toxicol, 2003, 33 (2) :105-136.

[46] TSUCHIDA T, LEE YA, FUJIWARA N, et al. A simple dietand chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer[J]. J Hepatol, 2018, 69 (2) :385-395.

[47] NUGENT C, YOUNOSSI ZM. Evaluation and management of obesity-related nonalcoholic fatty liver disease[J]. Nat Clin Pract Gastroenterol Hepatol, 2007, 4 (8) :432-441.

[48] FUJII M, SHIBAZAKI Y, WAKAMATSU K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma[J]. Med Mol Morphol, 2013, 46 (3) :141-152.

施引文献

资源附件(0)

访问统计